A photoreceptor pro-survival factor could buy AMD patients time, reducing or delaying photoreceptor degeneration, and the activin signaling pathway has already been identified as a promising druggable target for other therapeutic indications (reviewed in Tsuchida et al., 2009). This evidence concerns the gene INHBE and age-related macular degeneration.